Neuromedin U-25 (human) (trifluoroacetate salt)
(Synonyms: NMU-25) 目录号 : GC47768
A neuropeptide with diverse roles
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1 Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated roles in vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2 NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3 NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4
1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)
| Cas No. | N/A | SDF | |
| 别名 | NMU-25 | ||
| Canonical SMILES | NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@@H]1CCCN1C([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](NC([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@@H]2CCCN2C([C@H](CO)NC([C@H](CCC(N)=O)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@@H](NC([C@H](C(C)C)NC([C@H](CCCNC(N)=N)NC([C@@H](N[H])CC3=CC=CC=C3)=O)=O)=O)CC(O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)=O)CC5=CC=CC=C5)=O)C)=O)=O)=O)=O)=O)=O)CC6=CC=C(O)C=C6)=O)CC7=CC=CC=C7)=O)=O)CC8=CC=CC=C8)=O)=O)=O)=O)=O.FC(F)(C(O)=O)F | ||
| 分子式 | C141H203N41O38.XCF3COOH | 分子量 | 3080.4 |
| 溶解度 | DMF: 5 mg/ml,DMSO: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3246 mL | 1.6232 mL | 3.2463 mL |
| 5 mM | 0.0649 mL | 0.3246 mL | 0.6493 mL |
| 10 mM | 0.0325 mL | 0.1623 mL | 0.3246 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。